Experts anticipate a significant shift in Parkinson's disease treatment, with novel drugs aimed at slowing or even halting its progression potentially becoming available within three years. Alongside these disease-modifying therapies, improved symptom management drugs and a breakthrough blood test for early diagnosis could also emerge soon, heralding a new era for patients.
Parkinson's disease, a progressive neurological condition characterized by tremors, muscle stiffness, and movement difficulties, is the world's fastest-growing neurological disorder. Cases have increased by 38% in the UK over the past 15 years, and global figures are projected to double to over 12 million by 2040. Currently, there is no cure or approved drug that can slow the disease's advancement.
Targeting the Disease Itself
Scientists have gained a deeper understanding of how Parkinson's develops, identifying the accumulation of alpha synuclein protein as a key factor. These proteins form clusters that damage brain cells, reducing dopamine production crucial for movement control. This leads to the characteristic symptoms of Parkinson's, which can worsen over time and may include memory problems, sleep disturbances, depression, and dementia.
Six drugs are currently in Phase III trials, the final stage of testing before potential regulatory approval. Among these, prasinezumab, an antibody treatment, aims to bind to and prevent the spread of toxic alpha synuclein clumps. While an earlier trial showed mixed results, subsequent analyses indicated that it slowed disease progression by up to 55% in some patients over 2.5 years. This drug has demonstrated a strong safety profile.
Other promising treatments include ambroxol, a medication already licensed for respiratory conditions, which has shown potential to boost the clearance of waste products from brain cells. Several other drugs are also in late-stage trials, including telmisartan (a blood pressure medication), terazosin (for enlarged prostates), and UDSA (a liver and gallstone drug). These are being investigated in the EJS ACT-PD trial, which allows for multiple drugs to be tested concurrently.
Buntanetap, which reduces the production of toxic brain proteins, is also in late-stage trials. Furthermore, researchers are exploring the potential of GLP-1 drugs, commonly used for type 2 diabetes and weight loss, to reduce brain inflammation associated with Parkinson's.
Earlier Diagnosis and Improved Symptom Control
The development of a blood test capable of detecting early signs of Parkinson's up to seven years before symptoms emerge could revolutionize patient outcomes. Researchers have identified a pattern of proteins in the blood that indicates future development of the disease. Tests are underway to see if this pattern can be detected using a simple finger-prick blood sample, which could significantly reduce diagnostic waiting times and allow for earlier intervention.
In the shorter term, improvements in symptom management are also expected. Tavapadon, a once-daily pill designed to stimulate fewer dopamine receptors than existing drugs, may offer better symptom control with fewer side effects, such as compulsive behaviors. It is currently under review by the U.S. Food and Drug Administration and could be available in the UK as early as next year. Additionally, ondansetron, a drug used to manage chemotherapy-induced nausea, is being tested for its potential to reduce hallucinations, a distressing symptom for many Parkinson's patients.